The presentation places the EMERALD trial within the broader treatment context of metastatic ER+/HER2– disease. As resistance ...

An expert discusses how chronic kidney disease (CKD), often underdiagnosed and poorly recognized, is intricately linked with cardiovascular and metabolic conditions, emphasizing the urgent need for ...

The FDA has accepted for review Chiesi’s New Drug Application (NDA) for their investigational maintenance treatment for ...

A new report released by the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) examines the global and ...

The concept of a cure in oncology, particularly for stage II and III colon cancer (CC), has historically suffered from ...

In a single-center retrospective observational study at the Bari Polyclinic, researchers analyzed 50 adults with non-segmental vitiligo affecting 0.5 to 10% of their body surface area, including the ...

An expert discusses how treatment decisions must balance short-term burden with long-term benefits while avoiding protocol-driven step therapy requirements, as future comparative effectiveness trials ...

Panelists discuss how guselkumab demonstrated a very reassuring safety profile with no new safety signals or unexpected ...

New diagnostics, including lab tests and imaging, are revolutionizing medicine and creating exciting opportunities for ...

Biomarkers are pivotal for confirming diagnoses, predicting disease progression, and tailoring therapeutic modalities. Recent ...

An expert discusses how nonstatin therapies serve as essential tools when patients can’t tolerate statins or need additional ...

In this interview, Steven Buslovich, M.D., CMD, MS, chief medical officer of senior care at PointClickCare, explains the ...